Michael Elniski BecomesNew Vice President of ClearFlow Global Sales

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

ClearFlow, Inc., a medical device company based in Anaheim, California, has named Michael Elniski its new Vice President of Global Sales.

Elniski, who most recently served as Franchise VP of Cardiac Critical Care at Merit Medical and was previously VP of Healthcare Solutions at Edwards Lifesciences, is recognized for building sales organizations that consistently over-achieve sales goals. He brings to ClearFlow a rich expertise in developing commercial strategy and execution focused on competitive and disruptive medical device solutions.

“Michael has had a distinguished career to date, with major corporations in his wake, including 16 years at Edwards rising through the ranks from sales professional to executive leadership positions there and at Merit,” said Paul Molloy, CEO of ClearFlow. “His sales and commerce credentials are truly impressive but his work ethic, character and personality are what sealed our attraction to him. Michael is hard working, organized, disciplined and focused and brings years of medical device commercialization experience to ClearFlow. It’s a great fit and we look forward to reaping the benefits of his skills and expertise as we continue to grow and develop a world class sales organization befitting our innovative and disruptive science and technology.”

ClearFlow is the manufacturer of the PleuraFlow® Active Clearance Technology® (ACT®) System – the only FDA cleared device available that enables caregivers to proactively remove clots formed inside the chest tube to prevent or minimize chest tube occlusion with clot. A patent chest tube enables evacuation of blood and fluid from the operative site after closure of the surgical wound and reduces retained blood. Retained blood is accepted by physicians as contributing to many common complications after cardiac surgery, including post-operative atrial fibrillation (POAF), pleural effusions and pericardial effusions. PleuraFlow is used at the bedside in the ICU and enables caregivers to actively maintain chest tube patency following cardiac surgery.

The PleuraFlow ACT System is approved for use in the U.S., Europe, Australia, Brazil, Canada, Mexico and other countries in Asia and the Middle East.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.